Stocks in Focus on October 12: Delta Corp, Krsnaa Diagnostics, Tata Motors, Divi's Laboratories to Bharat Dynamics; here are the 5 Newsmakers of the Day

At the stock markets, the S&P BSE Sensex gained 76.72 points, or 0.13 per cent, to end at an all-time high of 60,135.78, on Monday, October 11, 2021. The Nifty 50 rose 50.75 points, or 0.28 per cent, to a record closing high of 17,945.95. Earlier in the intraday trade Nifty 50 crossed the 18,000-mark for the first time. But certain stocks came in the news after the market was closed. These stocks can impact the indices when it reopens on Tuesday, October 12, 2021. List of such five stocks:

Delta Corp: The company on Monday reported a consolidated net loss of Rs 22.57 crore for the quarter ended September 30, 2021 (Q2FY22). It had posted a consolidated loss of Rs 54.9 crore in the corresponding quarter of the previous financial year (Q2FY21). Revenue from operations grew 94.7% YoY to Rs 74.72 crore as against a revenue of Rs 38.37 crore posted last year. The company's earnings before interest, tax, depreciation and amortisation (EBITDA) loss stood at Rs 18.92 crore as against a loss of Rs 44.9 crore posted last year. 

See Zee Business Live TV Streaming Below:

Krsnaa Diagnostics + Tata Metaliks

Krsnaa Diagnostics: Pune-based diagnostic services provider Krsnaa Diagnostics on Monday reported a 44.69% YoY decline in profits at Rs 12.5 crore for the quarter ended September 30, 2021. It had posted a profit of Rs 22.6 crore in the corresponding quarter of the previous financial year. Sequentially, the profit declined 41.86% from Rs 21.5 crore posted in the previous quarter ended June 30, 2021 (Q1FY22). Revenue from operations dropped 28% YoY to Rs 108 crore as against Rs 150 crore posted last year. Sequentially, the revenue dropped 18.18% from Rs 132 crore posted in the previous quarter. EBITDA dropped 25.29% YoY to Rs 31.9 crore in the reported quarter from Rs 42.7 crore posted last year. EBITDA declined 23.37% sequentially from Rs 41.5 crore posted in Q1FY22. Margin stood at 29.5% in Q2FY22 as against 28.5% posted in Q2FY21. The margin stood at 31.4% in Q1FY22. 

Tata Metaliks: The manufacturer of pig iron and DI pipes has reported a 33.41% YoY decline in consolidated profits at Rs 54.6 crore for the quarter ended September 30, 2021. It had posted a profit of Rs 82 crore in the corresponding quarter of the previous financial year. Revenue from operations grew 24.28% YoY to Rs 645 crore as against Rs 519 crore posted last year. EBITDA stood at Rs 99.8 crore, down 8.82%, from Rs 109.45 crore posted last year. The margin of the company contracted to 15.5% in Q2FY22 from 21.1% posted in Q2FY21.  

Tata Motors + Hero MotoCorp

Tata Motors: The automotive manufacturer Tata Motors in its Q2FY22 global wholesale report said that the Tata Motors Group global wholesales in Q2FY22, including Jaguar Land Rover, were at 2,51,689 units, higher by 24%, as compared to Q2FY21. Global wholesales of all Tata Motors commercial vehicles and Tata Daewoo range in Q2FY22 were at 89,055 units, higher by 57%, over Q2 FY21. Global wholesales of all passenger vehicles in Q2 FY22 were at 1,62,634 units, higher by 11% as compared to Q2 FY21. Global wholesales for Jaguar Land Rover were 78,251 vehicles (JLR number for Q2 FY22 includes CJLR volumes of 14,219 units). Jaguar wholesales for the quarter were 13,944 vehicles, while Land Rover wholesales for the quarter were 64,307 vehicles. CJLR – It is a JV between JLR and Chery Automobiles and is an unconsolidated subsidiary for JLR
Hero MotoCorp: Aligned to its aggressive growth strategy in the scooter segment, Hero MotoCorp the world’s largest manufacturer of motorcycles and scooters, today launched the new Pleasure+ ‘XTec’. Hero Pleasure+ 110 will be available at Hero MotoCorp dealerships across the country at a starting price of Rs 61,900* for the LX variant and Pleasure+ 110 XTec starts at Rs 69,500*(Ex-Showroom, Delhi).

Divi's Laboratories: Drugmaker Merck has asked USFDA to authorise its pill against COVID-19, Molnupiravir. It would be the first pill shown to treat COVID-19. If approved, the US government could buy enough pills to treat 1.7 million people, at a price of roughly $700 for each course of treatment. Divi's Lab is the largest API supplier to Merck. 

Bharat Dynamics: Life Insurance Corporation (LIC) of India sold 2% stakes in the company, reducing its shareholding to 8.45% from 10.5%. The stakes were sold between September 8 to October 8, 2021.